Riluzole

Identification

Summary

Riluzole is a glutamate antagonist used to treat amyotrophic lateral sclerosis.

Brand Names

Exservan, Rilutek, Tiglutik

Generic Name

Riluzole

DrugBank Accession Number

DB00740

Background

A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Type

Small Molecule

Groups

Approved, Investigational

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Riluzole (DB00740)

×

Close

Weight

Average: 234.198
Monoisotopic: 234.007468097

Chemical Formula

C₈H₅F₃N₂OS

Synonyms

• Riluzol
• Riluzole
• Riluzolum

External IDs

• PK 26124
• RP 54274
• RPR 202

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Management of	Amyotrophic lateral sclerosis		••••••••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and/or time to tracheostomy. It is also neuroprotective in various in vivo experimental models of neuronal injury involving excitotoxic mechanisms. The etiology and pathogenesis of amyotrophic lateral sclerosis (ALS) are not known, although a number of hypotheses have been advanced. One hypothesis is that motor neurons, made vulnerable through either genetic predisposition or environmental factors, are injured by glutamate. In some cases of familial ALS the enzyme superoxide dismutase has been found to be defective.

Mechanism of action

The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.

Target	Actions	Organism
ASodium channel protein type 5 subunit alpha	inhibitor	Humans
ACystine/glutamate transporter	inducer	Humans

Absorption

Riluzole is well-absorbed (approximately 90%), with average absolute oral bioavailability of about 60% (CV=30%). A high fat meal decreases absorption, reducing AUC by about 20% and peak blood levels by about 45%.

Volume of distribution

Not Available

Protein binding

96% bound to plasma proteins, mainly to albumin and lipoprotein over the clinical concentration range.

Metabolism

Riluzole is extensively metabolized to six major and a number of minor metabolites, which have not all been identified to date. Metabolism is mostly hepatic, consisting of cytochrome P450–dependent hydroxylation and glucuronidation. CYP1A2 is the primary isozyme involved in N-hydroxylation; CYP2D6, CYP2C19, CYP3A4, and CYP2E1 are considered unlikely to contribute significantly to riluzole metabolism in humans.

Hover over products below to view reaction partners

• Riluzole
  • 4-OH-riluzole
  • 5-OH-riluzole
  • 7-OH-riluzole
  • N-OH-riluzole

Route of elimination

Not Available

Half-life

The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of CNS depression can be increased when Riluzole is combined with 1,2-Benzodiazepine.
Abametapir	The serum concentration of Riluzole can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Riluzole can be increased when combined with Abatacept.
Abemaciclib	Abemaciclib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Abiraterone	The serum concentration of Riluzole can be increased when it is combined with Abiraterone.
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Riluzole.
Acetaminophen	The metabolism of Riluzole can be decreased when combined with Acetaminophen.
Acetazolamide	The risk or severity of CNS depression can be increased when Riluzole is combined with Acetazolamide.
Acetophenazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Acetophenazine.
Acyclovir	The metabolism of Acyclovir can be decreased when combined with Riluzole.
Adalimumab	The metabolism of Riluzole can be increased when combined with Adalimumab.
Afatinib	Afatinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Agomelatine	The risk or severity of CNS depression can be increased when Riluzole is combined with Agomelatine.
Albendazole	The metabolism of Riluzole can be increased when combined with Albendazole.
Alectinib	Alectinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Alfentanil	The risk or severity of CNS depression can be increased when Riluzole is combined with Alfentanil.
Alimemazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Alimemazine.
Almotriptan	The risk or severity of CNS depression can be increased when Riluzole is combined with Almotriptan.
Alosetron	The metabolism of Riluzole can be decreased when combined with Alosetron.
Alprazolam	The risk or severity of CNS depression can be increased when Alprazolam is combined with Riluzole.
Alverine	The risk or severity of CNS depression can be increased when Riluzole is combined with Alverine.
Ambroxol	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Ambroxol.
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Riluzole.
Aminophylline	Riluzole may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.
Amiodarone	The metabolism of Riluzole can be decreased when combined with Amiodarone.
Amisulpride	The risk or severity of CNS depression can be increased when Riluzole is combined with Amisulpride.
Amitriptyline	The risk or severity of CNS depression can be increased when Amitriptyline is combined with Riluzole.
Amitriptylinoxide	The risk or severity of CNS depression can be increased when Riluzole is combined with Amitriptylinoxide.
Amobarbital	The risk or severity of CNS depression can be increased when Riluzole is combined with Amobarbital.
Amoxapine	The risk or severity of CNS depression can be increased when Amoxapine is combined with Riluzole.
Amphetamine	The therapeutic efficacy of Riluzole can be decreased when used in combination with Amphetamine.
Amphotericin B	The therapeutic efficacy of Riluzole can be decreased when used in combination with Amphotericin B.
Anagrelide	The metabolism of Riluzole can be decreased when combined with Anagrelide.
Anakinra	The metabolism of Riluzole can be increased when combined with Anakinra.
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Riluzole.
Apalutamide	The serum concentration of Riluzole can be decreased when it is combined with Apalutamide.
Apomorphine	The risk or severity of CNS depression can be increased when Apomorphine is combined with Riluzole.
Apremilast	The metabolism of Riluzole can be increased when combined with Apremilast.
Apronalide	The risk or severity of CNS depression can be increased when Riluzole is combined with Apronalide.
Aripiprazole	The risk or severity of CNS depression can be increased when Riluzole is combined with Aripiprazole.
Aripiprazole lauroxil	The risk or severity of CNS depression can be increased when Riluzole is combined with Aripiprazole lauroxil.
Armodafinil	The metabolism of Riluzole can be increased when combined with Armodafinil.
Articaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Articaine.
Asenapine	The risk or severity of CNS depression can be increased when Riluzole is combined with Asenapine.
Atazanavir	The metabolism of Riluzole can be decreased when combined with Atazanavir.
Atracurium	The risk or severity of CNS depression can be increased when Riluzole is combined with Atracurium.
Atracurium besylate	The risk or severity of CNS depression can be increased when Atracurium besylate is combined with Riluzole.
Avanafil	Avanafil may decrease the excretion rate of Riluzole which could result in a higher serum level.
Axitinib	The metabolism of Axitinib can be decreased when combined with Riluzole.
Azatadine	The therapeutic efficacy of Riluzole can be decreased when used in combination with Azatadine.
Azathioprine	The metabolism of Azathioprine can be decreased when combined with Riluzole.
Azelastine	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Azlocillin	The therapeutic efficacy of Riluzole can be decreased when used in combination with Azlocillin.
Baclofen	Baclofen may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Beclomethasone dipropionate	Beclomethasone dipropionate may decrease the excretion rate of Riluzole which could result in a higher serum level.
Belinostat	The metabolism of Riluzole can be increased when combined with Belinostat.
Belumosudil	Belumosudil may decrease the excretion rate of Riluzole which could result in a higher serum level.
Bendamustine	The metabolism of Bendamustine can be decreased when combined with Riluzole.
Benperidol	The risk or severity of CNS depression can be increased when Riluzole is combined with Benperidol.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Benzocaine.
Benzphetamine	The risk or severity of CNS depression can be increased when Riluzole is combined with Benzphetamine.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Benzyl alcohol.
Betaxolol	The metabolism of Riluzole can be decreased when combined with Betaxolol.
Bimekizumab	The metabolism of Riluzole can be increased when combined with Bimekizumab.
Binimetinib	The metabolism of Binimetinib can be decreased when combined with Riluzole.
Borage oil	The therapeutic efficacy of Riluzole can be decreased when used in combination with Borage oil.
Bortezomib	The metabolism of Riluzole can be decreased when combined with Bortezomib.
Botulinum toxin type A	The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Riluzole.
Botulinum toxin type B	The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Riluzole.
Brexanolone	The risk or severity of CNS depression can be increased when Riluzole is combined with Brexanolone.
Brexpiprazole	The risk or severity of CNS depression can be increased when Riluzole is combined with Brexpiprazole.
Brigatinib	Brigatinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Brivaracetam	The risk or severity of CNS depression can be increased when Riluzole is combined with Brivaracetam.
Bromazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Bromazepam.
Bromocriptine	The risk or severity of CNS depression can be increased when Riluzole is combined with Bromocriptine.
Bromotheophylline	Riluzole may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.
Bromperidol	The risk or severity of CNS depression can be increased when Riluzole is combined with Bromperidol.
Brompheniramine	The risk or severity of CNS depression can be increased when Riluzole is combined with Brompheniramine.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Bupivacaine.
Buprenorphine	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion	The risk or severity of CNS depression can be increased when Riluzole is combined with Bupropion.
Buspirone	The risk or severity of CNS depression can be increased when Buspirone is combined with Riluzole.
Butabarbital	The risk or severity of CNS depression can be increased when Butabarbital is combined with Riluzole.
Butacaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Butacaine.
Butalbital	The risk or severity of CNS depression can be increased when Butalbital is combined with Riluzole.
Butamben	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Butamben.
Butaperazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Butaperazine.
Butobarbital	The risk or severity of CNS depression can be increased when Riluzole is combined with Butobarbital.
Butorphanol	The risk or severity of CNS depression can be increased when Butorphanol is combined with Riluzole.
Butriptyline	The risk or severity of CNS depression can be increased when Riluzole is combined with Butriptyline.
Cabergoline	The risk or severity of CNS depression can be increased when Cabergoline is combined with Riluzole.
Caffeine	The metabolism of Riluzole can be decreased when combined with Caffeine.
Canakinumab	The metabolism of Riluzole can be increased when combined with Canakinumab.
Cannabidiol	The risk or severity of adverse effects can be increased when Cannabidiol is combined with Riluzole.
Capivasertib	Capivasertib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Capmatinib	The serum concentration of Riluzole can be increased when it is combined with Capmatinib.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Capsaicin.
Carbamazepine	Carbamazepine may increase the Change in thyroid function activities of Riluzole.
Carbinoxamine	The risk or severity of CNS depression can be increased when Riluzole is combined with Carbinoxamine.
Cariprazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Cariprazine.
Carisoprodol	The risk or severity of adverse effects can be increased when Carisoprodol is combined with Riluzole.
Carmustine	The metabolism of Riluzole can be decreased when combined with Carmustine.
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Riluzole.
Cefalotin	The therapeutic efficacy of Riluzole can be decreased when used in combination with Cefalotin.
Cefotaxime	The therapeutic efficacy of Riluzole can be decreased when used in combination with Cefotaxime.
Centella asiatica	The therapeutic efficacy of Riluzole can be decreased when used in combination with Centella asiatica.
Certolizumab pegol	The metabolism of Riluzole can be increased when combined with Certolizumab pegol.
Cetirizine	The risk or severity of CNS depression can be increased when Cetirizine is combined with Riluzole.
Chloral hydrate	The risk or severity of CNS depression can be increased when Riluzole is combined with Chloral hydrate.
Chlorambucil	The therapeutic efficacy of Riluzole can be decreased when used in combination with Chlorambucil.
Chlordiazepoxide	The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Riluzole.
Chlormezanone	The risk or severity of CNS depression can be increased when Riluzole is combined with Chlormezanone.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Chloroprocaine.
Chloroquine	The therapeutic efficacy of Riluzole can be decreased when used in combination with Chloroquine.
Chlorpheniramine	The risk or severity of CNS depression can be increased when Riluzole is combined with Chlorpheniramine.
Chlorpromazine	The risk or severity of CNS depression can be increased when Chlorpromazine is combined with Riluzole.
Chlorprothixene	The risk or severity of CNS depression can be increased when Riluzole is combined with Chlorprothixene.
Chlorzoxazone	The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Riluzole.
Cholesterol	Cholesterol may increase the excretion rate of Riluzole which could result in a lower serum level and potentially a reduction in efficacy.
Cilostazol	The metabolism of Cilostazol can be decreased when combined with Riluzole.
Cimetidine	The metabolism of Riluzole can be decreased when combined with Cimetidine.
Cinacalcet	The metabolism of Cinacalcet can be decreased when combined with Riluzole.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Cinchocaine.
Cinnarizine	The metabolism of Riluzole can be decreased when combined with Cinnarizine.
Cinoxacin	The metabolism of Riluzole can be decreased when combined with Cinoxacin.
Ciprofloxacin	The metabolism of Riluzole can be decreased when combined with Ciprofloxacin.
Cisapride	The risk or severity of CNS depression can be increased when Cisapride is combined with Riluzole.
Cisatracurium	The risk or severity of CNS depression can be increased when Cisatracurium is combined with Riluzole.
Citalopram	The risk or severity of adverse effects can be increased when Riluzole is combined with Citalopram.
Clemastine	The risk or severity of CNS depression can be increased when Clemastine is combined with Riluzole.
Clidinium	The risk or severity of CNS depression can be increased when Riluzole is combined with Clidinium.
Clobazam	The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Riluzole.
Clofazimine	Clofazimine may decrease the excretion rate of Riluzole which could result in a higher serum level.
Clomipramine	The risk or severity of CNS depression can be increased when Riluzole is combined with Clomipramine.
Clonazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Clonazepam.
Clonidine	The risk or severity of sedation can be increased when Clonidine is combined with Riluzole.
Clopidogrel	The metabolism of Clopidogrel can be decreased when combined with Riluzole.
Clorazepic acid	The risk or severity of CNS depression can be increased when Clorazepic acid is combined with Riluzole.
Clothiapine	The risk or severity of CNS depression can be increased when Riluzole is combined with Clothiapine.
Clotiazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Clotiazepam.
Clozapine	The risk or severity of CNS depression can be increased when Clozapine is combined with Riluzole.
Cobicistat	Cobicistat may decrease the excretion rate of Riluzole which could result in a higher serum level.
Cocaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Cocaine.
Codeine	The risk or severity of CNS depression can be increased when Codeine is combined with Riluzole.
Conjugated estrogens	The metabolism of Riluzole can be decreased when combined with Conjugated estrogens.
Curcumin	The metabolism of Riluzole can be decreased when combined with Curcumin.
Cyclizine	The risk or severity of CNS depression can be increased when Riluzole is combined with Cyclizine.
Cyclobenzaprine	The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Riluzole.
Cyclosporine	Cyclosporine may decrease the excretion rate of Riluzole which could result in a higher serum level.
Cyproheptadine	The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Riluzole.
Cyproterone acetate	The metabolism of Riluzole can be increased when combined with Cyproterone acetate.
Dabrafenib	Dabrafenib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Dacarbazine	The metabolism of Dacarbazine can be decreased when combined with Riluzole.
Daclatasvir	Daclatasvir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Dacomitinib	Dacomitinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Danicopan	The serum concentration of Riluzole can be increased when it is combined with Danicopan.
Dantrolene	The risk or severity of CNS depression can be increased when Riluzole is combined with Dantrolene.
Daridorexant	The risk or severity of CNS depression can be increased when Riluzole is combined with Daridorexant.
Darolutamide	The serum concentration of Riluzole can be increased when it is combined with Darolutamide.
Dasabuvir	Dasabuvir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Dasatinib	Dasatinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Decamethonium	The risk or severity of CNS depression can be increased when Riluzole is combined with Decamethonium.
Deferasirox	The serum concentration of Riluzole can be increased when it is combined with Deferasirox.
Desflurane	The risk or severity of CNS depression can be increased when Riluzole is combined with Desflurane.
Desipramine	The risk or severity of CNS depression can be increased when Riluzole is combined with Desipramine.
Desloratadine	The risk or severity of CNS depression can be increased when Riluzole is combined with Desloratadine.
Desogestrel	The metabolism of Desogestrel can be increased when combined with Riluzole.
Desvenlafaxine	The risk or severity of adverse effects can be increased when Riluzole is combined with Desvenlafaxine.
Dexamethasone	Dexamethasone may decrease the excretion rate of Riluzole which could result in a higher serum level.
Dexamethasone acetate	Dexamethasone acetate may decrease the excretion rate of Riluzole which could result in a higher serum level.
Dexbrompheniramine	The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Riluzole.
Dexchlorpheniramine maleate	The therapeutic efficacy of Riluzole can be decreased when used in combination with Dexchlorpheniramine maleate.
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Riluzole.
Dexmedetomidine	The risk or severity of CNS depression can be increased when Dexmedetomidine is combined with Riluzole.
Dexmethylphenidate	The risk or severity of CNS depression can be increased when Riluzole is combined with Dexmethylphenidate.
Dextromethorphan	The risk or severity of CNS depression can be increased when Dextromethorphan is combined with Riluzole.
Dextropropoxyphene	The risk or severity of CNS depression can be increased when Dextropropoxyphene is combined with Riluzole.
Dezocine	The risk or severity of CNS depression can be increased when Riluzole is combined with Dezocine.
Diacerein	The metabolism of Riluzole can be decreased when combined with Diacerein.
Diamorphine	The risk or severity of CNS depression can be increased when Riluzole is combined with Diamorphine.
Diazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Diazepam.
Dibenzepin	The risk or severity of CNS depression can be increased when Riluzole is combined with Dibenzepin.
Dichloralphenazone	The risk or severity of CNS depression can be increased when Riluzole is combined with Dichloralphenazone.
Diclofenac	The metabolism of Riluzole can be decreased when combined with Diclofenac.
Dienogest	The metabolism of Dienogest can be increased when combined with Riluzole.
Diethylpropion	The risk or severity of CNS depression can be increased when Riluzole is combined with Diethylpropion.
Diethylstilbestrol	The metabolism of Diethylstilbestrol can be increased when combined with Riluzole.
Difenoxin	The risk or severity of CNS depression can be increased when Riluzole is combined with Difenoxin.
Dihydralazine	The metabolism of Riluzole can be decreased when combined with Dihydralazine.
Dihydrocodeine	The risk or severity of CNS depression can be increased when Riluzole is combined with Dihydrocodeine.
Dihydroergotamine	The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Riluzole.
Dimenhydrinate	The risk or severity of CNS depression can be increased when Riluzole is combined with Dimenhydrinate.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Diphenhydramine.
Diphenoxylate	The risk or severity of CNS depression can be increased when Riluzole is combined with Diphenoxylate.
Disopyramide	The metabolism of Riluzole can be decreased when combined with Disopyramide.
Disulfiram	The therapeutic efficacy of Riluzole can be decreased when used in combination with Disulfiram.
Dolasetron	The risk or severity of CNS depression can be increased when Riluzole is combined with Dolasetron.
Domperidone	The metabolism of Domperidone can be decreased when combined with Riluzole.
Donepezil	The risk or severity of CNS depression can be increased when Riluzole is combined with Donepezil.
Dosulepin	The metabolism of Riluzole can be decreased when combined with Dosulepin.
Doxacurium	The risk or severity of CNS depression can be increased when Riluzole is combined with Doxacurium.
Doxepin	The risk or severity of CNS depression can be increased when Riluzole is combined with Doxepin.
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Drospirenone	The metabolism of Drospirenone can be increased when combined with Riluzole.
Duloxetine	The risk or severity of adverse effects can be increased when Riluzole is combined with Duloxetine.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Dyclonine.
Dyphylline	Riluzole may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.
Efavirenz	The risk or severity of CNS depression can be increased when Efavirenz is combined with Riluzole.
Elacestrant	The serum concentration of Riluzole can be increased when it is combined with Elacestrant.
Elbasvir	Elbasvir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Eletriptan	The risk or severity of CNS depression can be increased when Eletriptan is combined with Riluzole.
Eltrombopag	Eltrombopag may decrease the excretion rate of Riluzole which could result in a higher serum level.
Emapalumab	The metabolism of Riluzole can be increased when combined with Emapalumab.
Enasidenib	Enasidenib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Encorafenib	The serum concentration of Riluzole can be decreased when it is combined with Encorafenib.
Enflurane	The risk or severity of CNS depression can be increased when Enflurane is combined with Riluzole.
Enoxacin	The metabolism of Riluzole can be decreased when combined with Enoxacin.
Entacapone	The risk or severity of CNS depression can be increased when Entacapone is combined with Riluzole.
Entecavir	The metabolism of Riluzole can be decreased when combined with Entecavir.
Epcoritamab	The serum concentration of Riluzole can be increased when it is combined with Epcoritamab.
Epinastine	The risk or severity of CNS depression can be increased when Riluzole is combined with Epinastine.
Ergoloid mesylate	The risk or severity of CNS depression can be increased when Riluzole is combined with Ergoloid mesylate.
Ergometrine	The risk or severity of CNS depression can be increased when Riluzole is combined with Ergometrine.
Ergotamine	The risk or severity of CNS depression can be increased when Ergotamine is combined with Riluzole.
Erlotinib	Erlotinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Escitalopram	The risk or severity of adverse effects can be increased when Riluzole is combined with Escitalopram.
Esketamine	The risk or severity of adverse effects can be increased when Riluzole is combined with Esketamine.
Eslicarbazepine	The risk or severity of CNS depression can be increased when Riluzole is combined with Eslicarbazepine.
Eslicarbazepine acetate	The risk or severity of CNS depression can be increased when Riluzole is combined with Eslicarbazepine acetate.
Estazolam	The risk or severity of CNS depression can be increased when Riluzole is combined with Estazolam.
Estetrol	The therapeutic efficacy of Riluzole can be decreased when used in combination with Estetrol.
Estradiol	The metabolism of Estradiol can be increased when combined with Riluzole.
Estradiol acetate	Estradiol acetate may decrease the excretion rate of Riluzole which could result in a higher serum level.
Estradiol benzoate	The metabolism of Estradiol benzoate can be increased when combined with Riluzole.
Estradiol cypionate	The metabolism of Estradiol cypionate can be increased when combined with Riluzole.
Estradiol dienanthate	Estradiol dienanthate may decrease the excretion rate of Riluzole which could result in a higher serum level.
Estradiol valerate	The metabolism of Estradiol valerate can be increased when combined with Riluzole.
Estrone sulfate	The metabolism of Estrone sulfate can be increased when combined with Riluzole.
Eszopiclone	The risk or severity of CNS depression can be increased when Riluzole is combined with Eszopiclone.
Etanercept	The metabolism of Riluzole can be increased when combined with Etanercept.
Ethambutol	The metabolism of Riluzole can be decreased when combined with Ethambutol.
Ethanol	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol	The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Riluzole.
Ethinylestradiol	The metabolism of Ethinylestradiol can be increased when combined with Riluzole.
Ethosuximide	The risk or severity of CNS depression can be increased when Ethosuximide is combined with Riluzole.
Ethotoin	The risk or severity of CNS depression can be increased when Riluzole is combined with Ethotoin.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Ethyl chloride.
Ethynodiol diacetate	The metabolism of Ethynodiol diacetate can be increased when combined with Riluzole.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Etidocaine.
Etomidate	The risk or severity of CNS depression can be increased when Etomidate is combined with Riluzole.
Etonogestrel	The metabolism of Etonogestrel can be increased when combined with Riluzole.
Etoposide	The metabolism of Etoposide can be decreased when combined with Riluzole.
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Riluzole.
Ezogabine	The risk or severity of CNS depression can be increased when Riluzole is combined with Ezogabine.
Famotidine	The metabolism of Riluzole can be decreased when combined with Famotidine.
Febuxostat	The excretion of Riluzole can be decreased when combined with Febuxostat.
Fedratinib	Fedratinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Felbamate	The risk or severity of CNS depression can be increased when Riluzole is combined with Felbamate.
Fenfluramine	The risk or severity of CNS depression can be increased when Fenfluramine is combined with Riluzole.
Fentanyl	The risk or severity of CNS depression can be increased when Riluzole is combined with Fentanyl.
Fexinidazole	The metabolism of Riluzole can be decreased when combined with Fexinidazole.
Fezolinetant	The metabolism of Fezolinetant can be decreased when combined with Riluzole.
Flecainide	The metabolism of Flecainide can be decreased when combined with Riluzole.
Flibanserin	The risk or severity of CNS depression can be increased when Riluzole is combined with Flibanserin.
Flunarizine	The risk or severity of CNS depression can be increased when Riluzole is combined with Flunarizine.
Flunitrazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Flunitrazepam.
Fluorouracil	The metabolism of Riluzole can be decreased when combined with Fluorouracil.
Fluoxetine	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.
Flupentixol	The risk or severity of CNS depression can be increased when Riluzole is combined with Flupentixol.
Fluphenazine	The risk or severity of CNS depression can be increased when Fluphenazine is combined with Riluzole.
Flurazepam	The risk or severity of CNS depression can be increased when Flurazepam is combined with Riluzole.
Fluspirilene	The risk or severity of CNS depression can be increased when Riluzole is combined with Fluspirilene.
Flutamide	The metabolism of Riluzole can be decreased when combined with Flutamide.
Fluticasone propionate	The risk or severity of CNS depression can be increased when Fluticasone propionate is combined with Riluzole.
Fluvoxamine	The metabolism of Riluzole can be decreased when combined with Fluvoxamine.
Fosphenytoin	The risk or severity of CNS depression can be increased when Riluzole is combined with Fosphenytoin.
Fospropofol	The risk or severity of CNS depression can be increased when Riluzole is combined with Fospropofol.
Fostamatinib	Fostamatinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Fostemsavir	Fostemsavir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Frovatriptan	The risk or severity of CNS depression can be increased when Riluzole is combined with Frovatriptan.
Fusidic acid	Fusidic acid may decrease the excretion rate of Riluzole which could result in a higher serum level.
Gabapentin	The risk or severity of CNS depression can be increased when Riluzole is combined with Gabapentin.
Gabapentin enacarbil	The risk or severity of CNS depression can be increased when Riluzole is combined with Gabapentin enacarbil.
Gallamine triethiodide	The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Riluzole.
gamma-Hydroxybutyric acid	The risk or severity of CNS depression can be increased when Riluzole is combined with gamma-Hydroxybutyric acid.
Gamolenic acid	The therapeutic efficacy of Riluzole can be decreased when used in combination with Gamolenic acid.
Ganaxolone	The risk or severity of sedation, somnolence, and CNS depression can be increased when Riluzole is combined with Ganaxolone.
Ganciclovir	The therapeutic efficacy of Riluzole can be decreased when used in combination with Ganciclovir.
Gatifloxacin	The metabolism of Riluzole can be decreased when combined with Gatifloxacin.
Gefitinib	Gefitinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Gemfibrozil	The metabolism of Riluzole can be decreased when combined with Gemfibrozil.
Gemifloxacin	The metabolism of Riluzole can be decreased when combined with Gemifloxacin.
Gepirone	The risk or severity of CNS depression can be increased when Riluzole is combined with Gepirone.
Gestrinone	The metabolism of Gestrinone can be increased when combined with Riluzole.
Gilteritinib	Gilteritinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Givosiran	The serum concentration of Riluzole can be increased when it is combined with Givosiran.
Glasdegib	Glasdegib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Glecaprevir	Glecaprevir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Glofitamab	The serum concentration of Riluzole can be increased when it is combined with Glofitamab.
Glutethimide	The risk or severity of CNS depression can be increased when Riluzole is combined with Glutethimide.
Golimumab	The metabolism of Riluzole can be increased when combined with Golimumab.
Granisetron	The risk or severity of CNS depression can be increased when Riluzole is combined with Granisetron.
Grazoprevir	Grazoprevir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Grepafloxacin	The metabolism of Riluzole can be decreased when combined with Grepafloxacin.
Guanabenz	The metabolism of Riluzole can be decreased when combined with Guanabenz.
Guanfacine	The risk or severity of CNS depression can be increased when Riluzole is combined with Guanfacine.
Halazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Halazepam.
Halofantrine	The therapeutic efficacy of Riluzole can be decreased when used in combination with Halofantrine.
Haloperidol	The risk or severity of CNS depression can be increased when Haloperidol is combined with Riluzole.
Halothane	The risk or severity of CNS depression can be increased when Riluzole is combined with Halothane.
Hexafluronium	The risk or severity of CNS depression can be increased when Riluzole is combined with Hexafluronium.
Hydrocodone	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone	The risk or severity of CNS depression can be increased when Hydromorphone is combined with Riluzole.
Hydroxychloroquine	The therapeutic efficacy of Riluzole can be decreased when used in combination with Hydroxychloroquine.
Hydroxyprogesterone caproate	The metabolism of Hydroxyprogesterone caproate can be increased when combined with Riluzole.
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Iloperidone	The risk or severity of CNS depression can be increased when Riluzole is combined with Iloperidone.
Imatinib	Imatinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Imipenem	The therapeutic efficacy of Riluzole can be decreased when used in combination with Imipenem.
Imipramine	The metabolism of Riluzole can be decreased when combined with Imipramine.
Infliximab	The metabolism of Riluzole can be increased when combined with Infliximab.
Insulin beef	The metabolism of Riluzole can be increased when combined with Insulin beef.
Insulin pork	The metabolism of Riluzole can be increased when combined with Insulin pork.
Interferon alfa-2a	The metabolism of Riluzole can be decreased when combined with Interferon alfa-2a.
Interferon alfa-2b	The metabolism of Riluzole can be decreased when combined with Interferon alfa-2b.
Interferon alfa-n1	The metabolism of Riluzole can be decreased when combined with Interferon alfa-n1.
Interferon alfa-n3	The metabolism of Riluzole can be decreased when combined with Interferon alfa-n3.
Interferon alfacon-1	The metabolism of Riluzole can be decreased when combined with Interferon alfacon-1.
Interferon beta-1a	The metabolism of Riluzole can be decreased when combined with Interferon beta-1a.
Interferon beta-1b	The metabolism of Riluzole can be decreased when combined with Interferon beta-1b.
Interferon gamma-1b	The metabolism of Riluzole can be decreased when combined with Interferon gamma-1b.
Iohexol	The therapeutic efficacy of Riluzole can be decreased when used in combination with Iohexol.
Isavuconazole	Isavuconazole may decrease the excretion rate of Riluzole which could result in a higher serum level.
Isavuconazonium	Isavuconazonium may decrease the excretion rate of Riluzole which could result in a higher serum level.
Isocarboxazid	The risk or severity of CNS depression can be increased when Riluzole is combined with Isocarboxazid.
Isoflurane	The risk or severity of CNS depression can be increased when Riluzole is combined with Isoflurane.
Isoniazid	The metabolism of Riluzole can be decreased when combined with Isoniazid.
Istradefylline	Istradefylline may decrease the excretion rate of Riluzole which could result in a higher serum level.
Itraconazole	Itraconazole may decrease the excretion rate of Riluzole which could result in a higher serum level.
Ketamine	The risk or severity of CNS depression can be increased when Riluzole is combined with Ketamine.
Ketazolam	The risk or severity of CNS depression can be increased when Riluzole is combined with Ketazolam.
Ketoconazole	The metabolism of Riluzole can be decreased when combined with Ketoconazole.
Lamotrigine	The risk or severity of CNS depression can be increased when Lamotrigine is combined with Riluzole.
Lansoprazole	Lansoprazole may decrease the excretion rate of Riluzole which could result in a higher serum level.
Lasmiditan	The serum concentration of Riluzole can be increased when it is combined with Lasmiditan.
Ledipasvir	Ledipasvir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Leflunomide	The serum concentration of Riluzole can be decreased when it is combined with Leflunomide.
Lemborexant	The risk or severity of CNS depression can be increased when Riluzole is combined with Lemborexant.
Leniolisib	The excretion of Riluzole can be decreased when combined with Leniolisib.
Levacetylmethadol	The risk or severity of CNS depression can be increased when Riluzole is combined with Levacetylmethadol.
Levetiracetam	The risk or severity of CNS depression can be increased when Riluzole is combined with Levetiracetam.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Levobupivacaine.
Levocetirizine	The risk or severity of CNS depression can be increased when Riluzole is combined with Levocetirizine.
Levodopa	The risk or severity of CNS depression can be increased when Riluzole is combined with Levodopa.
Levonorgestrel	The metabolism of Levonorgestrel can be increased when combined with Riluzole.
Levorphanol	The risk or severity of CNS depression can be increased when Riluzole is combined with Levorphanol.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Lidocaine.
Linezolid	The therapeutic efficacy of Riluzole can be decreased when used in combination with Linezolid.
Lisuride	The risk or severity of CNS depression can be increased when Lisuride is combined with Riluzole.
Lithium carbonate	The risk or severity of CNS depression can be increased when Riluzole is combined with Lithium carbonate.
Lofexidine	The therapeutic efficacy of Riluzole can be increased when used in combination with Lofexidine.
Lomefloxacin	The metabolism of Lomefloxacin can be decreased when combined with Riluzole.
Lomifylline	Riluzole may increase the excretion rate of Lomifylline which could result in a lower serum level and potentially a reduction in efficacy.
Lonapegsomatropin	The metabolism of Riluzole can be increased when combined with Lonapegsomatropin.
Lorazepam	The risk or severity of CNS depression can be increased when Lorazepam is combined with Riluzole.
Lorcaserin	The risk or severity of CNS depression can be increased when Riluzole is combined with Lorcaserin.
Lormetazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Lormetazepam.
Loxapine	The risk or severity of CNS depression can be increased when Loxapine is combined with Riluzole.
Lumateperone	The risk or severity of CNS depression can be increased when Riluzole is combined with Lumateperone.
Lurasidone	The risk or severity of CNS depression can be increased when Riluzole is combined with Lurasidone.
Lynestrenol	The metabolism of Lynestrenol can be increased when combined with Riluzole.
Magnesium sulfate	The therapeutic efficacy of Riluzole can be increased when used in combination with Magnesium sulfate.
Maprotiline	The risk or severity of CNS depression can be increased when Riluzole is combined with Maprotiline.
Maribavir	Maribavir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Mazindol	The risk or severity of CNS depression can be increased when Mazindol is combined with Riluzole.
Mebutamate	The risk or severity of CNS depression can be increased when Riluzole is combined with Mebutamate.
Meclizine	The risk or severity of CNS depression can be increased when Meclizine is combined with Riluzole.
Medifoxamine	The risk or severity of CNS depression can be increased when Riluzole is combined with Medifoxamine.
Medroxyprogesterone acetate	The metabolism of Medroxyprogesterone acetate can be increased when combined with Riluzole.
Mefenamic acid	The metabolism of Mefenamic acid can be decreased when combined with Riluzole.
Mefloquine	The therapeutic efficacy of Riluzole can be decreased when used in combination with Mefloquine.
Megestrol acetate	The metabolism of Megestrol acetate can be increased when combined with Riluzole.
Melatonin	The risk or severity of CNS depression can be increased when Riluzole is combined with Melatonin.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Meloxicam.
Meperidine	The risk or severity of CNS depression can be increased when Meperidine is combined with Riluzole.
Mephenytoin	The risk or severity of CNS depression can be increased when Mephenytoin is combined with Riluzole.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Mepivacaine.
Meprobamate	The risk or severity of CNS depression can be increased when Meprobamate is combined with Riluzole.
Mepyramine	The risk or severity of CNS depression can be increased when Riluzole is combined with Mepyramine.
Mercaptopurine	Riluzole may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.
Mesoridazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Mesoridazine.
Mestranol	The metabolism of Mestranol can be increased when combined with Riluzole.
Metaxalone	The risk or severity of CNS depression can be increased when Metaxalone is combined with Riluzole.
Metergoline	The risk or severity of CNS depression can be increased when Riluzole is combined with Metergoline.
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Riluzole.
Methdilazine	The therapeutic efficacy of Riluzole can be decreased when used in combination with Methdilazine.
Methimazole	The metabolism of Riluzole can be decreased when combined with Methimazole.
Methocarbamol	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Riluzole.
Methohexital	The risk or severity of CNS depression can be increased when Methohexital is combined with Riluzole.
Methotrimeprazine	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxsalen	The metabolism of Riluzole can be decreased when combined with Methoxsalen.
Methoxyflurane	The risk or severity of CNS depression can be increased when Riluzole is combined with Methoxyflurane.
Methsuximide	The risk or severity of CNS depression can be increased when Riluzole is combined with Methsuximide.
Methylene blue	The risk or severity of CNS depression can be increased when Riluzole is combined with Methylene blue.
Methylphenidate	The therapeutic efficacy of Riluzole can be decreased when used in combination with Methylphenidate.
Methylphenobarbital	The risk or severity of CNS depression can be increased when Riluzole is combined with Methylphenobarbital.
Methyprylon	The risk or severity of CNS depression can be increased when Riluzole is combined with Methyprylon.
Methysergide	The risk or severity of CNS depression can be increased when Methysergide is combined with Riluzole.
Metoclopramide	The risk or severity of sedation can be increased when Metoclopramide is combined with Riluzole.
Metocurine	The risk or severity of CNS depression can be increased when Riluzole is combined with Metocurine.
Metocurine iodide	The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Riluzole.
Metronidazole	The therapeutic efficacy of Riluzole can be decreased when used in combination with Metronidazole.
Metyrosine	Riluzole may increase the sedative activities of Metyrosine.
Mexiletine	The metabolism of Riluzole can be decreased when combined with Mexiletine.
Mianserin	The therapeutic efficacy of Riluzole can be decreased when used in combination with Mianserin.
Midazolam	The risk or severity of sedation and CNS depression can be increased when Midazolam is combined with Riluzole.
Mifepristone	The metabolism of Mifepristone can be increased when combined with Riluzole.
Milnacipran	The risk or severity of adverse effects can be increased when Riluzole is combined with Milnacipran.
Minaprine	The risk or severity of CNS depression can be increased when Riluzole is combined with Minaprine.
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Mirtazapine	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mivacurium	The risk or severity of CNS depression can be increased when Riluzole is combined with Mivacurium.
Moclobemide	The risk or severity of CNS depression can be increased when Riluzole is combined with Moclobemide.
Molindone	The risk or severity of CNS depression can be increased when Riluzole is combined with Molindone.
Momelotinib	The serum concentration of Riluzole can be increased when it is combined with Momelotinib.
Moricizine	The risk or severity of CNS depression can be increased when Moricizine is combined with Riluzole.
Morphine	The risk or severity of CNS depression can be increased when Morphine is combined with Riluzole.
Moxifloxacin	The metabolism of Riluzole can be decreased when combined with Moxifloxacin.
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Nabumetone	The metabolism of Riluzole can be decreased when combined with Nabumetone.
Nafcillin	The metabolism of Riluzole can be increased when combined with Nafcillin.
Nalbuphine	The risk or severity of CNS depression can be increased when Riluzole is combined with Nalbuphine.
Nalidixic acid	The metabolism of Riluzole can be decreased when combined with Nalidixic acid.
Naproxen	The metabolism of Naproxen can be decreased when combined with Riluzole.
Naratriptan	The risk or severity of CNS depression can be increased when Riluzole is combined with Naratriptan.
Nefazodone	The risk or severity of adverse effects can be increased when Riluzole is combined with Nefazodone.
Nelfinavir	Nelfinavir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Nevirapine	The metabolism of Riluzole can be decreased when combined with Nevirapine.
Nialamide	The risk or severity of CNS depression can be increased when Riluzole is combined with Nialamide.
Niclosamide	The metabolism of Riluzole can be decreased when combined with Niclosamide.
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Riluzole.
Nilotinib	Nilotinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Nitrazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Nitrazepam.
Nitrous oxide	The risk or severity of CNS depression can be increased when Riluzole is combined with Nitrous oxide.
Nomegestrol	The metabolism of Nomegestrol can be increased when combined with Riluzole.
Nomegestrol acetate	The metabolism of Nomegestrol acetate can be increased when combined with Riluzole.
Nomifensine	The risk or severity of CNS depression can be increased when Riluzole is combined with Nomifensine.
Nonoxynol-9	The metabolism of Nonoxynol-9 can be increased when combined with Riluzole.
Norelgestromin	The metabolism of Norelgestromin can be increased when combined with Riluzole.
Norethisterone	The metabolism of Norethisterone can be increased when combined with Riluzole.
Norethynodrel	The metabolism of Norethynodrel can be increased when combined with Riluzole.
Norfloxacin	The metabolism of Riluzole can be decreased when combined with Norfloxacin.
Norgestimate	The metabolism of Norgestimate can be increased when combined with Riluzole.
Norgestrel	The metabolism of Norgestrel can be increased when combined with Riluzole.
Normethadone	The risk or severity of CNS depression can be increased when Riluzole is combined with Normethadone.
Nortriptyline	The risk or severity of CNS depression can be increased when Nortriptyline is combined with Riluzole.
Novobiocin	Novobiocin may decrease the excretion rate of Riluzole which could result in a higher serum level.
Obeticholic acid	The metabolism of Riluzole can be decreased when combined with Obeticholic acid.
Olanzapine	The risk or severity of CNS depression can be increased when Olanzapine is combined with Riluzole.
Oliceridine	The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Riluzole is combined with Oliceridine.
Ondansetron	The risk or severity of CNS depression can be increased when Riluzole is combined with Ondansetron.
Opium	The risk or severity of CNS depression can be increased when Riluzole is combined with Opium.
Orlistat	Orlistat can cause a decrease in the absorption of Riluzole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Orphenadrine	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osilodrostat	The metabolism of Riluzole can be decreased when combined with Osilodrostat.
Osimertinib	The serum concentration of Riluzole can be decreased when it is combined with Osimertinib.
Oteseconazole	The serum concentration of Riluzole can be increased when it is combined with Oteseconazole.
Oxazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Oxazepam.
Oxcarbazepine	The risk or severity of CNS depression can be increased when Riluzole is combined with Oxcarbazepine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Oxetacaine.
Oxitriptan	The risk or severity of CNS depression can be increased when Riluzole is combined with Oxitriptan.
Oxprenolol	The risk or severity of CNS depression can be increased when Riluzole is combined with Oxprenolol.
Oxtriphylline	Riluzole may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Oxybuprocaine.
Oxycodone	The risk or severity of CNS depression can be increased when Oxycodone is combined with Riluzole.
Oxymorphone	The risk or severity of CNS depression can be increased when Riluzole is combined with Oxymorphone.
Pacritinib	The serum concentration of Riluzole can be increased when it is combined with Pacritinib.
Palbociclib	Palbociclib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Paliperidone	The risk or severity of CNS depression can be increased when Riluzole is combined with Paliperidone.
Palonosetron	The risk or severity of CNS depression can be increased when Palonosetron is combined with Riluzole.
Pancuronium	The risk or severity of CNS depression can be increased when Riluzole is combined with Pancuronium.
Pantoprazole	Pantoprazole may decrease the excretion rate of Riluzole which could result in a higher serum level.
Paraldehyde	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paramethadione	The risk or severity of CNS depression can be increased when Paramethadione is combined with Riluzole.
Pargyline	The risk or severity of CNS depression can be increased when Riluzole is combined with Pargyline.
Paritaprevir	Paritaprevir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Paroxetine	The risk or severity of adverse effects can be increased when Riluzole is combined with Paroxetine.
Pazopanib	The metabolism of Pazopanib can be decreased when combined with Riluzole.
Pefloxacin	The metabolism of Riluzole can be decreased when combined with Pefloxacin.
Peginterferon alfa-2a	The metabolism of Riluzole can be decreased when combined with Peginterferon alfa-2a.
Peginterferon alfa-2b	The serum concentration of Riluzole can be increased when it is combined with Peginterferon alfa-2b.
Pemetrexed	The metabolism of Riluzole can be decreased when combined with Pemetrexed.
Penbutolol	The risk or severity of CNS depression can be increased when Riluzole is combined with Penbutolol.
Penciclovir	The metabolism of Riluzole can be decreased when combined with Penciclovir.
Pentazocine	The risk or severity of CNS depression can be increased when Pentazocine is combined with Riluzole.
Pentobarbital	The risk or severity of CNS depression can be increased when Pentobarbital is combined with Riluzole.
Pentoxifylline	Riluzole may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Perazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Perazine.
Pergolide	The risk or severity of CNS depression can be increased when Riluzole is combined with Pergolide.
Periciazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Periciazine.
Perphenazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Perphenazine.
Phenacemide	The risk or severity of CNS depression can be increased when Riluzole is combined with Phenacemide.
Phenelzine	The risk or severity of CNS depression can be increased when Riluzole is combined with Phenelzine.
Phenobarbital	The risk or severity of CNS depression can be increased when Riluzole is combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Phenol.
Phensuximide	The risk or severity of CNS depression can be increased when Riluzole is combined with Phensuximide.
Phenylephrine	The metabolism of Riluzole can be increased when combined with Phenylephrine.
Phenylpropanolamine	The therapeutic efficacy of Riluzole can be decreased when used in combination with Phenylpropanolamine.
Phenytoin	The risk or severity of CNS depression can be increased when Phenytoin is combined with Riluzole.
Pibrentasvir	Pibrentasvir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Pimozide	The risk or severity of CNS depression can be increased when Riluzole is combined with Pimozide.
Pindolol	The risk or severity of CNS depression can be increased when Riluzole is combined with Pindolol.
Pipecuronium	The risk or severity of CNS depression can be increased when Riluzole is combined with Pipecuronium.
Pipotiazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Pipotiazine.
Pirfenidone	The metabolism of Pirfenidone can be decreased when combined with Riluzole.
Piritramide	The risk or severity of CNS depression can be increased when Riluzole is combined with Piritramide.
Pirtobrutinib	Pirtobrutinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Pitolisant	The metabolism of Riluzole can be increased when combined with Pitolisant.
Pizotifen	The risk or severity of CNS depression can be increased when Riluzole is combined with Pizotifen.
Pomalidomide	The risk or severity of CNS depression can be increased when Riluzole is combined with Pomalidomide.
Ponatinib	Ponatinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Pralsetinib	Pralsetinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Pramipexole	Riluzole may increase the sedative activities of Pramipexole.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Pramocaine.
Pravastatin	Pravastatin may decrease the excretion rate of Riluzole which could result in a higher serum level.
Prazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Prazepam.
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Riluzole.
Pregabalin	The therapeutic efficacy of Riluzole can be increased when used in combination with Pregabalin.
Pretomanid	The serum concentration of Riluzole can be increased when it is combined with Pretomanid.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Prilocaine.
Primaquine	The metabolism of Riluzole can be increased when combined with Primaquine.
Primidone	The metabolism of Riluzole can be increased when combined with Primidone.
Procaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Procaine.
Procarbazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Procarbazine.
Prochlorperazine	The risk or severity of CNS depression can be increased when Prochlorperazine is combined with Riluzole.
Progesterone	The metabolism of Progesterone can be increased when combined with Riluzole.
Promazine	The risk or severity of CNS depression can be increased when Promazine is combined with Riluzole.
Promethazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Promethazine.
Propafenone	The metabolism of Riluzole can be decreased when combined with Propafenone.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Proparacaine.
Propiomazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Propiomazine.
Propofol	The risk or severity of CNS depression can be increased when Riluzole is combined with Propofol.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Propoxycaine.
Propranolol	The metabolism of Riluzole can be decreased when combined with Propranolol.
Protriptyline	The risk or severity of CNS depression can be increased when Protriptyline is combined with Riluzole.
Proxibarbal	The risk or severity of CNS depression can be increased when Riluzole is combined with Proxibarbal.
Pyrantel	The risk or severity of CNS depression can be increased when Riluzole is combined with Pyrantel.
Quazepam	The risk or severity of CNS depression can be increased when Riluzole is combined with Quazepam.
Quetiapine	The risk or severity of CNS depression can be increased when Riluzole is combined with Quetiapine.
Quinidine	The metabolism of Riluzole can be decreased when combined with Quinidine.
Quinine	The risk or severity of CNS depression can be increased when Quinine is combined with Riluzole.
Quinupramine	The risk or severity of CNS depression can be increased when Riluzole is combined with Quinupramine.
Rabeprazole	Rabeprazole may decrease the excretion rate of Riluzole which could result in a higher serum level.
Ramelteon	The risk or severity of CNS depression can be increased when Riluzole is combined with Ramelteon.
Ranitidine	The metabolism of Ranitidine can be decreased when combined with Riluzole.
Rapacuronium	The risk or severity of CNS depression can be increased when Riluzole is combined with Rapacuronium.
Rasagiline	The risk or severity of CNS depression can be increased when Riluzole is combined with Rasagiline.
Reboxetine	The risk or severity of CNS depression can be increased when Reboxetine is combined with Riluzole.
Regorafenib	Regorafenib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Remifentanil	The risk or severity of CNS depression can be increased when Riluzole is combined with Remifentanil.
Remimazolam	The risk or severity of CNS depression can be increased when Riluzole is combined with Remimazolam.
Remoxipride	The risk or severity of CNS depression can be increased when Remoxipride is combined with Riluzole.
Repotrectinib	Repotrectinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Reserpine	The risk or severity of CNS depression can be increased when Reserpine is combined with Riluzole.
Rifampin	The metabolism of Riluzole can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Riluzole can be decreased when combined with Rifamycin.
Rilonacept	The metabolism of Riluzole can be increased when combined with Rilonacept.
Rilpivirine	Rilpivirine may decrease the excretion rate of Riluzole which could result in a higher serum level.
Rimonabant	The risk or severity of adverse effects can be increased when Rimonabant is combined with Riluzole.
Ripretinib	Ripretinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Risperidone	The risk or severity of CNS depression can be increased when Risperidone is combined with Riluzole.
Ritlecitinib	The serum concentration of Riluzole can be increased when it is combined with Ritlecitinib.
Ritonavir	Ritonavir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Rocuronium	The risk or severity of CNS depression can be increased when Rocuronium is combined with Riluzole.
Rofecoxib	The metabolism of Riluzole can be decreased when combined with Rofecoxib.
Roflumilast	The metabolism of Roflumilast can be decreased when combined with Riluzole.
Rolapitant	Rolapitant may decrease the excretion rate of Riluzole which could result in a higher serum level.
Ropeginterferon alfa-2b	The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Riluzole.
Ropinirole	Riluzole may increase the sedative activities of Ropinirole.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Ropivacaine.
Rosoxacin	The metabolism of Riluzole can be decreased when combined with Rosoxacin.
Rotigotine	Riluzole may increase the sedative activities of Rotigotine.
Roxadustat	The serum concentration of Riluzole can be increased when it is combined with Roxadustat.
Rucaparib	Rucaparib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Riluzole.
Safinamide	The risk or severity of CNS depression can be increased when Riluzole is combined with Safinamide.
Samidorphan	The risk or severity of CNS depression can be increased when Riluzole is combined with Samidorphan.
Saquinavir	Saquinavir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Satralizumab	The serum concentration of Riluzole can be decreased when it is combined with Satralizumab.
Scopolamine	The risk or severity of CNS depression can be increased when Riluzole is combined with Scopolamine.
Secobarbital	The risk or severity of CNS depression can be increased when Secobarbital is combined with Riluzole.
Secukinumab	The metabolism of Riluzole can be increased when combined with Secukinumab.
Segesterone acetate	The metabolism of Segesterone acetate can be increased when combined with Riluzole.
Selegiline	The risk or severity of CNS depression can be increased when Riluzole is combined with Selegiline.
Selumetinib	The metabolism of Selumetinib can be decreased when combined with Riluzole.
Sertindole	The risk or severity of CNS depression can be increased when Riluzole is combined with Sertindole.
Sertraline	The risk or severity of adverse effects can be increased when Riluzole is combined with Sertraline.
Sevoflurane	The risk or severity of CNS depression can be increased when Riluzole is combined with Sevoflurane.
Sibutramine	The risk or severity of adverse effects can be increased when Riluzole is combined with Sibutramine.
Siltuximab	The metabolism of Riluzole can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Riluzole can be decreased when combined with Simeprevir.
Sodium oxybate	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium phosphate, monobasic	The therapeutic efficacy of Riluzole can be decreased when used in combination with Sodium phosphate, monobasic.
Solriamfetol	The risk or severity of CNS depression can be increased when Riluzole is combined with Solriamfetol.
Somapacitan	The metabolism of Riluzole can be increased when combined with Somapacitan.
Somatotropin	The metabolism of Riluzole can be increased when combined with Somatotropin.
Somatrem	The metabolism of Riluzole can be increased when combined with Somatrem.
Somatrogon	The metabolism of Riluzole can be increased when combined with Somatrogon.
Sorafenib	The metabolism of Riluzole can be decreased when combined with Sorafenib.
Sotagliflozin	Sotagliflozin may decrease the excretion rate of Riluzole which could result in a higher serum level.
Sotorasib	The serum concentration of Riluzole can be increased when it is combined with Sotorasib.
Sparsentan	Sparsentan may decrease the excretion rate of Riluzole which could result in a higher serum level.
St. John's Wort	The risk or severity of CNS depression can be increased when Riluzole is combined with St. John's Wort.
Stiripentol	The excretion of Riluzole can be decreased when combined with Stiripentol.
Succinylcholine	The risk or severity of CNS depression can be increased when Succinylcholine is combined with Riluzole.
Sufentanil	The risk or severity of CNS depression can be increased when Sufentanil is combined with Riluzole.
Sulfasalazine	Sulfasalazine may decrease the excretion rate of Riluzole which could result in a higher serum level.
Sulpiride	The risk or severity of CNS depression can be increased when Sulpiride is combined with Riluzole.
Sulthiame	The risk or severity of CNS depression can be increased when Riluzole is combined with Sulthiame.
Sultopride	The risk or severity of CNS depression can be increased when Riluzole is combined with Sultopride.
Sumatriptan	The risk or severity of CNS depression can be increased when Sumatriptan is combined with Riluzole.
Sunitinib	Sunitinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Suvorexant	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tacrine	The metabolism of Riluzole can be decreased when combined with Tacrine.
Tafamidis	The serum concentration of Riluzole can be increased when it is combined with Tafamidis.
Talbutal	The risk or severity of CNS depression can be increased when Talbutal is combined with Riluzole.
Tamoxifen	The metabolism of Riluzole can be decreased when combined with Tamoxifen.
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Riluzole.
Tasimelteon	The risk or severity of CNS depression can be increased when Riluzole is combined with Tasimelteon.
Taurocholic acid	Taurocholic acid may decrease the excretion rate of Riluzole which could result in a higher serum level.
Tegafur	The metabolism of Tegafur can be decreased when combined with Riluzole.
Tegaserod	The metabolism of Riluzole can be decreased when combined with Tegaserod.
Telmisartan	Telmisartan may decrease the excretion rate of Riluzole which could result in a higher serum level.
Temazepam	The risk or severity of CNS depression can be increased when Temazepam is combined with Riluzole.
Tenofovir alafenamide	The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Riluzole.
Tepotinib	Tepotinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Riluzole.
Teriflunomide	The serum concentration of Riluzole can be decreased when it is combined with Teriflunomide.
Testosterone enanthate	The metabolism of Testosterone enanthate can be increased when combined with Riluzole.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Tetracaine.
Tetracosactide	The risk or severity of liver damage can be increased when Tetracosactide is combined with Riluzole.
Thalidomide	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline	Riluzole may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.
Thiabendazole	The metabolism of Riluzole can be decreased when combined with Thiabendazole.
Thiamylal	The risk or severity of CNS depression can be increased when Riluzole is combined with Thiamylal.
Thiethylperazine	The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Riluzole.
Thiopental	The risk or severity of CNS depression can be increased when Thiopental is combined with Riluzole.
Thioridazine	The risk or severity of CNS depression can be increased when Thioridazine is combined with Riluzole.
Thiothixene	The risk or severity of CNS depression can be increased when Riluzole is combined with Thiothixene.
Tiagabine	The risk or severity of CNS depression can be increased when Riluzole is combined with Tiagabine.
Ticlopidine	The metabolism of Riluzole can be decreased when combined with Ticlopidine.
Tivozanib	Tivozanib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Tizanidine	The risk or severity of CNS depression can be increased when Tizanidine is combined with Riluzole.
Tocainide	The metabolism of Tocainide can be decreased when combined with Riluzole.
Tocilizumab	The metabolism of Riluzole can be increased when combined with Tocilizumab.
Tolcapone	The risk or severity of CNS depression can be increased when Tolcapone is combined with Riluzole.
Topiramate	The risk or severity of CNS depression can be increased when Topiramate is combined with Riluzole.
Topotecan	Riluzole may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Tramadol	The risk or severity of CNS depression can be increased when Riluzole is combined with Tramadol.
Tranylcypromine	The risk or severity of CNS depression can be increased when Riluzole is combined with Tranylcypromine.
Trazodone	The risk or severity of adverse effects can be increased when Riluzole is combined with Trazodone.
Triamterene	The metabolism of Riluzole can be decreased when combined with Triamterene.
Triazolam	The risk or severity of CNS depression can be increased when Riluzole is combined with Triazolam.
Trichloroethylene	The risk or severity of CNS depression can be increased when Riluzole is combined with Trichloroethylene.
Triclabendazole	The metabolism of Riluzole can be decreased when combined with Triclabendazole.
Triclofos	The risk or severity of CNS depression can be increased when Riluzole is combined with Triclofos.
Trifluoperazine	The risk or severity of CNS depression can be increased when Riluzole is combined with Trifluoperazine.
Triflupromazine	The risk or severity of CNS depression can be increased when Triflupromazine is combined with Riluzole.
Trilaciclib	The metabolism of Riluzole can be increased when combined with Trilaciclib.
Trimethadione	The risk or severity of CNS depression can be increased when Trimethadione is combined with Riluzole.
Trimethobenzamide	The risk or severity of CNS depression can be increased when Trimethobenzamide is combined with Riluzole.
Trimipramine	The risk or severity of CNS depression can be increased when Trimipramine is combined with Riluzole.
Triprolidine	The risk or severity of CNS depression can be increased when Triprolidine is combined with Riluzole.
Tropisetron	The risk or severity of CNS depression can be increased when Riluzole is combined with Tropisetron.
Trovafloxacin	The metabolism of Riluzole can be decreased when combined with Trovafloxacin.
Tryptophan	The risk or severity of CNS depression can be increased when Tryptophan is combined with Riluzole.
Tubocurarine	The risk or severity of CNS depression can be increased when Riluzole is combined with Tubocurarine.
Ulipristal	The metabolism of Ulipristal can be increased when combined with Riluzole.
Urethane	The risk or severity of CNS depression can be increased when Riluzole is combined with Urethane.
Vadadustat	Vadadustat may decrease the excretion rate of Riluzole which could result in a higher serum level.
Valganciclovir	The therapeutic efficacy of Riluzole can be decreased when used in combination with Valganciclovir.
Valproic acid	The risk or severity of CNS depression can be increased when Valproic acid is combined with Riluzole.
Vandetanib	Vandetanib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Vecuronium	The risk or severity of CNS depression can be increased when Riluzole is combined with Vecuronium.
Velpatasvir	Velpatasvir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Vemurafenib	The serum concentration of Riluzole can be increased when it is combined with Vemurafenib.
Venetoclax	Venetoclax may decrease the excretion rate of Riluzole which could result in a higher serum level.
Venlafaxine	The risk or severity of CNS depression can be increased when Venlafaxine is combined with Riluzole.
Verapamil	The metabolism of Riluzole can be decreased when combined with Verapamil.
Vigabatrin	The risk or severity of CNS depression can be increased when Riluzole is combined with Vigabatrin.
Vilazodone	The risk or severity of CNS depression can be increased when Riluzole is combined with Vilazodone.
Viloxazine	The metabolism of Riluzole can be decreased when combined with Viloxazine.
Vismodegib	Vismodegib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Vortioxetine	The risk or severity of CNS depression can be increased when Riluzole is combined with Vortioxetine.
Voxilaprevir	Voxilaprevir may decrease the excretion rate of Riluzole which could result in a higher serum level.
Warfarin	The metabolism of Riluzole can be decreased when combined with Warfarin.
Yohimbine	The risk or severity of CNS depression can be increased when Riluzole is combined with Yohimbine.
Zaleplon	The risk or severity of CNS depression can be increased when Riluzole is combined with Zaleplon.
Ziconotide	The risk or severity of CNS depression can be increased when Riluzole is combined with Ziconotide.
Zileuton	The metabolism of Riluzole can be decreased when combined with Zileuton.
Zimelidine	The risk or severity of adverse effects can be increased when Riluzole is combined with Zimelidine.
Ziprasidone	The risk or severity of adverse effects can be increased when Riluzole is combined with Ziprasidone.
Zolmitriptan	The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Riluzole.
Zolpidem	Riluzole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide	The risk or severity of CNS depression can be increased when Riluzole is combined with Zonisamide.
Zopiclone	The risk or severity of adverse effects can be increased when Riluzole is combined with Zopiclone.
Zotepine	The risk or severity of CNS depression can be increased when Riluzole is combined with Zotepine.
Zuclopenthixol	The risk or severity of CNS depression can be increased when Riluzole is combined with Zuclopenthixol.
Zuranolone	The risk or severity of CNS depression can be increased when Zuranolone is combined with Riluzole.

Food Interactions

• Take on an empty stomach. Take at least 1 hour before or 2 hours after meals.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Riluzole Hydrochloride	Not Available	Not Available	QEAOELIJQRYJJS-UHFFFAOYSA-N

Product Images

International/Other Brands

Fanizan (Actavis) / Laidec (Sun Pro) / Lizolorol (Actavis) / Lizorolol (ratiopharm) / Rilustad (STADA) / Sclefic (Actavis) / Xie Yi Li (Lunan Pharm) / Zolerilis (Actavis)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Exservan	Film	50 mg/1	Oral	Mitsubishi Tanabe Pharma America, Inc.	2021-05-01	Not applicable
Exservan	Film	50 mg/1	Oral	Aquestive Therapeutics	2019-01-24	Not applicable
Exservan	Film	50 mg/1	Oral	Mitsubishi Tanabe Pharma America, Inc.	2021-05-01	Not applicable
Rilutek	Tablet, film coated	50 mg	Oral	SANOFI WINTHROP INDUSTRIE	2016-09-08	Not applicable
Rilutek	Tablet, film coated	50 mg/1	Oral	sanofi-aventis U.S. LLC	1995-12-12	2015-06-30
Rilutek	Tablet	50 mg/1	Oral	Covis Pharma US, Inc	2016-08-01	2024-05-31
Rilutek	Tablet	50 mg/1	Oral	Covis Pharmaceuticals, Inc.	2013-07-15	2017-12-13
Rilutek	Tablet	50 mg	Oral	Sanofi Aventis	2000-10-26	Not applicable
Rilutek	Tablet	50 mg/1	Oral	KAISER FOUNDATION HOSPITALS	2014-01-20	2014-12-31
Riluzole Zentiva	Tablet, film coated	50 mg	Oral	Zentiva K.S.	2016-09-08	Not applicable
Riluzole Zentiva	Tablet, film coated	50 mg	Oral	Zentiva K.S.	2016-09-08	Not applicable
Riluzole Zentiva	Tablet, film coated	50 mg	Oral	Zentiva K.S.	2016-09-08	Not applicable
Riluzole Zentiva	Tablet, film coated	50 mg	Oral	Zentiva K.S.	2016-09-08	Not applicable
Riluzole Zentiva	Tablet, film coated	50 mg	Oral	Zentiva K.S.	2016-09-08	Not applicable
Teglutik	Liquid	5 mg/1mL	Oral	EDW PHARMA	2024-03-08	Not applicable
Teglutik	Liquid	50 mg/10mL	Oral	EDW PHARMA, INC	2024-01-19	Not applicable
Tiglutik	Liquid	50 mg/10mL	Oral	EDW PHARMA, INC	2018-09-21	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Apo-riluzole	Tablet	50 mg	Oral	Apotex Corporation	2012-09-25	Not applicable
Mylan-riluzole	Tablet	50 mg	Oral	Mylan Pharmaceuticals	2012-10-23	Not applicable
Riluzole	Tablet	50 mg/1	Oral	Ascend Laboratories, LLC	2016-03-31	Not applicable
Riluzole	Tablet, film coated	50 mg/1	Oral	AvKARE	2020-10-07	Not applicable
Riluzole	Tablet	50 mg/1	Oral	KAISER FOUNDATION HOSPITALS	2016-09-29	2018-08-31
Riluzole	Tablet, film coated	50 mg/1	Oral	Glenmark Pharmaceuticals Inc., USA	2013-06-18	Not applicable
Riluzole	Tablet, film coated	50 mg/1	Oral	Rising Pharmaceuticals, Inc.	2013-05-15	Not applicable
Riluzole	Tablet, film coated	50 mg/1	Oral	Impax Generics	2003-01-29	2016-11-18
Riluzole	Tablet, film coated	50 mg/1	Oral	Quinn Pharmaceuticals	2020-01-01	Not applicable
Riluzole	Tablet, film coated	50 mg/1	Oral	Apotex Corp	2013-06-18	2021-10-31
Riluzole	Tablet	50 mg/1	Oral	Quinn Pharmaceuticals, Llc	2019-01-14	Not applicable
Riluzole	Tablet, film coated	50 mg/1	Oral	Sun Pharmaceutical Industries, Inc.	2013-06-18	Not applicable
Riluzole	Tablet, film coated	50 mg/1	Oral	KAISER FOUNDATION HOSPITALS	2014-05-14	2016-11-30
Riluzole	Tablet, film coated	50 mg/1	Oral	Av Kare, Inc.	2014-01-08	2016-08-04
Riluzole	Tablet, film coated	50 mg/1	Oral	American Health Packaging	2015-03-31	2020-10-31
Riluzole	Tablet, film coated	50 mg/1	Oral	Mylan Pharmaceuticals Inc.	2013-07-22	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Teglutik	Riluzole (5 mg/1mL)	Liquid	Oral	EDW PHARMA	2024-03-08	Not applicable
Teglutik	Riluzole (50 mg/10mL)	Liquid	Oral	EDW PHARMA, INC	2024-01-19	Not applicable

Categories

ATC Codes

N07XX02 — Riluzole

• N07XX — Other nervous system drugs
• N07X — OTHER NERVOUS SYSTEM DRUGS
• N07 — OTHER NERVOUS SYSTEM DRUGS
• N — NERVOUS SYSTEM

Drug Categories

• Anticonvulsants
• BCRP/ABCG2 Substrates
• Benzothiazoles
• Central Nervous System Agents
• Central Nervous System Depressants
• Compounds used in a research, industrial, or household setting
• Cytochrome P-450 CYP1A2 Substrates
• Cytochrome P-450 Substrates
• Excitatory Amino Acid Agents
• Excitatory Amino Acid Antagonists
• Heterocyclic Compounds, Fused-Ring
• Miscellaneous Central Nervous System Agents
• Nervous System
• Neuroprotective Agents
• Neurotransmitter Agents
• Protective Agents
• Sulfur Compounds
• Thiazoles

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as benzothiazoles. These are organic compounds containing a benzene fused to a thiazole ring (a five-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Benzothiazoles

Sub Class

Not Available

Direct Parent

Benzothiazoles

Alternative Parents

Benzenoids / 2-amino-1,3-thiazoles / Heteroaromatic compounds / Trihalomethanes / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organooxygen compounds / Organofluorides / Hydrocarbon derivatives / Alkyl fluorides

show 1 more

Substituents

1,3-benzothiazole / 1,3-thiazol-2-amine / Alkyl fluoride / Alkyl halide / Amine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Halomethane / Heteroaromatic compound / Hydrocarbon derivative / Organic nitrogen compound / Organic oxygen compound / Organofluoride / Organohalogen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Primary amine / Thiazole / Trihalomethane

show 12 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

benzothiazoles (CHEBI:8863)

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

7LJ087RS6F

CAS number

1744-22-5

InChI Key

FTALBRSUTCGOEG-UHFFFAOYSA-N

InChI

InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)

IUPAC Name

6-(trifluoromethoxy)-1,3-benzothiazol-2-amine

SMILES

NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2

References

Synthesis Reference

Pratap Padi, Madhusudhan Ganta, Satyanarayana Bollikonda, Sridhar Chaganti, Ramulu Akula, Loka Maheshwari Dommati, "PROCESS FOR PREPARING RILUZOLE." U.S. Patent US20080108827, issued May 08, 2008.

US20080108827

General References

1. Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T: Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther. 1997 Aug;282(2):707-14. [Article]
2. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH: Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005 Sep 1;58(5):424-8. [Article]
3. van Kan HJ, Groeneveld GJ, Kalmijn S, Spieksma M, van den Berg LH, Guchelaar HJ: Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. Br J Clin Pharmacol. 2005 Mar;59(3):310-3. [Article]
4. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK: An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004 Jan;161(1):171-4. [Article]
5. Mathew SJ, Manji HK, Charney DS: Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. doi: 10.1038/sj.npp.1301652. Epub 2008 Jan 2. [Article]
6. Lamanauskas N, Nistri A: Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci. 2008 May;27(10):2501-14. doi: 10.1111/j.1460-9568.2008.06211.x. Epub 2008 Apr 26. [Article]
7. FDA Approved Drug Products: RILUTEK (riluzole) tablets [Link]
8. FDA Approved Drug Products: EXSERVAN (riluzole) film [Link]
9. FDA Approved Drug Products: TIGLUTIK (riluzole) suspension [Link]

External Links

Human Metabolome Database

HMDB0014878

KEGG Drug

D00775

KEGG Compound

C07937

PubChem Compound

5070

PubChem Substance

46508094

ChemSpider

4892

BindingDB

30705

RxNav

35623

ChEBI

8863

ChEMBL

CHEMBL744

ZINC

ZINC000000006481

Therapeutic Targets Database

DAP000527

PharmGKB

PA451251

Guide to Pharmacology

GtP Drug Page

PDBe Ligand

657

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Riluzole

PDB Entries

5v02 / 7bnj / 7wdb / 8thg

FDA label

Download (125 KB)

MSDS

Download (29.5 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
4	Completed	Treatment	Fatigue / Inflammation	1
4	Completed	Treatment	Fragile X Syndrome	1
4	Completed	Treatment	Gilles de la Tourette's Syndrome	1
4	Completed	Treatment	Major Depressive Disorder (MDD)	1
4	Terminated	Treatment	Memory Disturbances / Mood	1
3	Active Not Recruiting	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
3	Completed	Other	Amyotrophic Lateral Sclerosis (ALS)	1
3	Completed	Treatment	Cervical Spondylotic Myelopathy	1
3	Completed	Treatment	Huntington's Disease (HD)	1
3	Completed	Treatment	Spinocerebellar Ataxias Type 2	1
3	Recruiting	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
3	Terminated	Treatment	Multiple System Atrophy (MSA) / Progressive Supranuclear Palsy (PSP)	1
2	Active Not Recruiting	Prevention	Oxaliplatin-induced Peripheral Neuropathy	1
2	Active Not Recruiting	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
2	Completed	Prevention	Multiple Sclerosis	1
2	Completed	Treatment	Alzheimer's Disease (AD)	1
2	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS)	6
2	Completed	Treatment	Aspergers Syndrome / Autism Disorder / Developmental Delay / Obsessive Compulsive Disorder (OCD)	1
2	Completed	Treatment	Ataxia, Cerebellar / Hereditary Ataxia / Multiple Sclerosis	1
2	Completed	Treatment	Autism Disorder	1
2	Completed	Treatment	Bipolar Disorder (BD)	1
2	Completed	Treatment	Depression	2
2	Completed	Treatment	Melanoma	1
2	Completed	Treatment	Obsessive Compulsive Disorder (OCD)	1
2	Completed	Treatment	Secondary Progressive Multiple Sclerosis (SPMS)	1
2	Recruiting	Prevention	Paroxysmal Atrial Fibrillation (PAF)	1
2	Recruiting	Treatment	Spinal Cord Injuries	1
2	Terminated	Other	Amyotrophic Lateral Sclerosis (ALS)	1
2	Terminated	Treatment	Anxiety Disorders / Bipolar Affective Disorders / Bipolar Disorder (BD) / Depression, Bipolar	1
2	Terminated	Treatment	Bipolar Disorder (BD)	1
2	Terminated	Treatment	Major Depressive Disorder (MDD)	1
2	Withdrawn	Other	Amyotrophic Lateral Sclerosis (ALS)	1
2, 3	Completed	Other	Performance Anxiety / Social Anxiety Disorder (SAD)	1
2, 3	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS)	2
2, 3	Completed	Treatment	Ataxia, Cerebellar	1
2, 3	Completed	Treatment	Spinal Muscular Atrophy (SMA)	1
2, 3	Recruiting	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
2, 3	Terminated	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
2, 3	Terminated	Treatment	Spinal Cord Injuries	1
2, 3	Unknown Status	Treatment	Neuromuscular Disorders	1
2, 3	Unknown Status	Treatment	SCA7	1
1	Active Not Recruiting	Treatment	Advanced Malignant Solid Tumor / Recurrent Melanoma / Refractory Malignant Solid Neoplasm / Stage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IV Cutaneous Melanoma AJCC v6 and v7	1
1	Active Not Recruiting	Treatment	Stage IV Colorectal Cancer / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8	1
1	Completed	Treatment	Bioequivalence	1
1	Completed	Treatment	Post Traumatic Stress Disorder (PTSD)	1
1	Terminated	Treatment	Melanoma	1
1	Terminated	Treatment	Metastatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Withdrawn	Treatment	Breast Cancer	1
1, 2	Completed	Treatment	Post Traumatic Stress Disorder (PTSD)	1
1, 2	Terminated	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
0	Completed	Basic Science	Autism Disorder	1
0	Completed	Basic Science	Post Traumatic Stress Disorder (PTSD)	1
0	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
0	Recruiting	Basic Science	Healthy (Controls) / Treatment Resistant Schizophrenia / Treatment-responsive Schizophrenia	1
Not Available	Completed	Not Available	Spinal Cord Injuries	1
Not Available	Completed	Basic Science	Amyotrophic Lateral Sclerosis (ALS)	1
Not Available	Completed	Treatment	Depression, Bipolar	1
Not Available	Completed	Treatment	Schizoaffective / Schizophrenia	1
Not Available	No Longer Available	Not Available	Amyotrophic Lateral Sclerosis (ALS)	1
Not Available	Unknown Status	Basic Science	Spinal Cord Injury, Chronic	1

Pharmacoeconomics

Manufacturers

• Sanofi aventis us llc
• Impax laboratories inc

Packagers

• Inyx Usa Ltd.
• Kaiser Foundation Hospital
• Sanofi-Aventis Inc.
• Southwood Pharmaceuticals

Dosage Forms

Form	Route	Strength
Film	Oral	50 MG
Tablet	Oral
Film	Oral	50 mg/1
Tablet	Oral	50.00 mg
Tablet, coated	Oral	50 mg
Tablet, film coated	Oral	50 mg
Tablet, coated	Oral	5000000 mg
Tablet	Oral	50 mg
Tablet, film coated	Oral
Tablet	Oral	50 mg/1
Tablet, film coated	Oral	50 mg/1
Liquid	Oral	5 mg/1mL
Suspension	Oral	5 MG/ML
Suspension	Oral
Suspension	Oral	0.5 mg
Liquid	Oral	50 mg/10mL

Prices

Unit description	Cost	Unit
Rilutek 50 mg tablet	18.77USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US5527814	No	1996-06-18	2013-06-18
CA2151604	No	2005-09-20	2013-12-10
CA2117466	No	2000-01-25	2012-10-22
US8603514	No	2013-12-10	2024-04-03
US8765150	No	2014-07-01	2029-03-12
US8765167	No	2014-07-01	2024-02-20

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	119 °C	Not Available
logP	2.3	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0395 mg/mL	ALOGPS
logP	2.83	ALOGPS
logP	3.4	Chemaxon
logS	-3.8	ALOGPS
pKa (Strongest Acidic)	16.44	Chemaxon
pKa (Strongest Basic)	4.57	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	3	Chemaxon
Hydrogen Donor Count	1	Chemaxon
Polar Surface Area	48.14 Å2	Chemaxon
Rotatable Bond Count	2	Chemaxon
Refractivity	44.37 m3·mol-1	Chemaxon
Polarizability	18.59 Å3	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.995
Blood Brain Barrier	+	0.9799
Caco-2 permeable	-	0.5377
P-glycoprotein substrate	Non-substrate	0.8045
P-glycoprotein inhibitor I	Non-inhibitor	0.8245
P-glycoprotein inhibitor II	Non-inhibitor	0.6998
Renal organic cation transporter	Non-inhibitor	0.859
CYP450 2C9 substrate	Non-substrate	0.8679
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Non-substrate	0.7032
CYP450 1A2 substrate	Inhibitor	0.9106
CYP450 2C9 inhibitor	Non-inhibitor	0.9072
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.8332
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.6647
Ames test	AMES toxic	0.6799
Carcinogenicity	Non-carcinogens	0.9001
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	3.6843 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9775
hERG inhibition (predictor II)	Non-inhibitor	0.8734

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-00li-2940000000-00c484cbc92e6a94bae0
MS/MS Spectrum - , positive	LC-MS/MS	splash10-000i-2590000000-5a9d0f7cdad7e4f2ec6b
MS/MS Spectrum - , positive	LC-MS/MS	splash10-000i-0390000000-4bd44ae3d25f047943e8
MS/MS Spectrum - , positive	LC-MS/MS	splash10-000i-3940000000-1da38288b84e863a64e5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-000i-0090000000-7843c01132bccbbab8fa
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-001i-0090000000-2972f1ebcacdf4db0736
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-000i-0090000000-82f022cd37921d0ac71e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-001i-0090000000-f522253a86d418326dd0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0bt9-1690000000-3f361795c0ce2867a1ca
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0a4i-9210000000-ebd8914ee14afccf5af7
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	137.8325092	predicted	DarkChem Lite v0.1.0
[M-H]-	143.85353	predicted	DeepCCS 1.0 (2019)
[M+H]+	137.5397092	predicted	DarkChem Lite v0.1.0
[M+H]+	146.21153	predicted	DeepCCS 1.0 (2019)
[M+Na]+	138.5174092	predicted	DarkChem Lite v0.1.0
[M+Na]+	152.46223	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Sodium channel protein type 5 subunit alpha

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

General Function

Voltage-gated sodium channel activity involved in sa node cell action potential

Specific Function

This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...

Gene Name

SCN5A

Uniprot ID

Q14524

Uniprot Name

Sodium channel protein type 5 subunit alpha

Molecular Weight

226937.475 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
3. Schwartz G, Fehlings MG: Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90. [Article]
4. Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T: Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther. 1997 Aug;282(2):707-14. [Article]
5. Weiss S, Benoist D, White E, Teng W, Saint DA: Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current. Br J Pharmacol. 2010 Jul;160(5):1072-82. doi: 10.1111/j.1476-5381.2010.00766.x. [Article]

Details2. Cystine/glutamate transporter

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inducer

General Function

Cystine:glutamate antiporter activity

Specific Function

Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate.

Gene Name

SLC7A11

Uniprot ID

Q9UPY5

Uniprot Name

Cystine/glutamate transporter

Molecular Weight

55422.44 Da

References

1. Wokke J: Riluzole. Lancet. 1996 Sep 21;348(9030):795-9. [Article]
2. Azbill RD, Mu X, Springer JE: Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res. 2000 Jul 21;871(2):175-80. [Article]
3. Dunlop J, Beal McIlvain H, She Y, Howland DS: Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci. 2003 Mar 1;23(5):1688-96. [Article]
4. Gosselin RD, O'Connor RM, Tramullas M, Julio-Pieper M, Dinan TG, Cryan JF: Riluzole normalizes early-life stress-induced visceral hypersensitivity in rats: role of spinal glutamate reuptake mechanisms. Gastroenterology. 2010 Jun;138(7):2418-25. doi: 10.1053/j.gastro.2010.03.003. Epub 2010 Mar 10. [Article]
5. Hayashida K, Parker RA, Eisenach JC: Activation of glutamate transporters in the locus coeruleus paradoxically activates descending inhibition in rats. Brain Res. 2010 Mar 4;1317:80-6. doi: 10.1016/j.brainres.2009.12.086. Epub 2010 Jan 6. [Article]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 13, 2005 13:24 / Updated at May 24, 2024 22:12